Neuroform Atlas Stent System
Stryker Neurovascular · Decision date Oct 24, 2026
What did the FDA approve?
FDA approved supplement S012 to PMA P180031 for the Neuroform Atlas Stent System on October 24, 2026. The supplement covers a manufacturing site at Nitinol Devices and Components Costa Rica, S.R.L., Building B28, El Coyol, Alajuela 20102 Costa Rica, for postlaser cutting operations of the Neuroform Atlas stent component.
This is a location change for a manufacturer, not a new approval of the whole system. The stated scope is limited to postlaser cutting operations at the named Costa Rica site. The source statement does not describe any change to indications, labeling, design, or clinical data, and it does not provide evidence of safety or effectiveness beyond the administrative approval record.
FDA approval order statement
approval for a manufacturing site located at Nitinol Devices and Components Costa Rica, S.R.L., Building B28, El Coyol, Alajuela 20102 Costa Rica for the postlaser cutting operations of the Neuroform Atlas stent component
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Oct 24, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P180031/S012
- Regulatory pathway
- PMA supplement
- Applicant
- Stryker Neurovascular
- Product code
- QCA
- Decision code
- APPR
- Decision date
- Oct 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intracranial coil-assist stent.
- Applicant
- Stryker Neurovascular
- Product code
- QCA
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P180031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P180031 · Original PMA
Neuroform Atlas Stent System
P180031/S012 received
Application receipt date recorded by FDA.
P180031/S012 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P180031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Neuroform Atlas Stent SystemP180031 | Stryker Neurovascular | PMA approval | May 16, 2019 | FDA |
Explore the linked device profile
Other records with product code QCA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Microvention, Inc. | PMA supplement | Sep 16, 2026 | FDA | |
| Microvention, Inc. | PMA approval | May 30, 2018 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Stryker Neurovascular
- Headquarters
- Not reported
- Brand website
- stryker.com
- FDA applicant address
- 47900 Bayside Pkwy., Fremont, CA, 94538
Sources and methodology
- Original FDA record: P180031/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

